RxDoctor Payments Data

Lacretia Daniels, NP

Nurse Practitioner · Wentzville, MONPI 1518103654

Payments from drug & device makers

$2,838in general payments, 2019–2025

Across 84 payments — averaging $33.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$601
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$374
  • Boston Scientific$344
  • Novartis$273
  • E.r. Squibb & Sons, L.L.C.$208
  • Novo Nordisk$163
  • plus $874 from 17 others

What the payments were for

  • Food & beverage$2,78898%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,838 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$16,367
Medicare patients
142
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$34,011
JardianceEmpagliflozin27$28,213
EntrestoSacubitril/Valsartan21$24,199
Metoprolol Succinate76$568
Nitroglycerin28$499
Atorvastatin Calcium63$363
Furosemide43$233
Ezetimibe18$224
Amlodipine Besylate39$222
Carvedilol34$207
Losartan Potassium32$204
ClopidogrelClopidogrel Bisulfate38$186
Isosorbide Mononitrate ErIsosorbide Mononitrate19$141
Rosuvastatin Calcium12$116
Lisinopril14$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$34,01127 claims
Boehringer IngelheimJardiance$42$28,21327 claims
NovartisEntresto$273$24,19921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Wentzville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →